FISHER & PAYKEL HEALTHCARE CORPORATION LIMITED (FPH)
Share Price Analysis and Chart
Enter the company code or Name for stock analysis:
FPH - FISHER & PAYKEL HEALTHCARE CORPORATION LIMITED
FNArena Sector :
Medical Equipment & Devices
Year End: March
GICS Industry Group : Health Care Equipment & Services
Debt/EBITDA: 0.34
Index: ASX100 | ASX200 | ASX300 | ALL-ORDS
FNArena Sector : Medical Equipment & Devices
Year End: March
GICS Industry Group : Health Care Equipment & Services
Debt/EBITDA: 0.34
Fisher & Paykel Healthcare is a designer and manufacturer of systems used in respiratory care and treatment of sleep disorders. It was separated from Fisher & Paykel and listed on the ASX and NZX in 2001. A brief Nasdaq listing was terminated in 2003. Only 1% of its revenues stems from New Zealand.
LAST PRICE | CHANGE +/- | CHANGE % | VOLUME |
---|---|---|---|
$26.20
07 May |
0.100 OPEN $26.40 |
0.38% HIGH $26.40 |
140,305 LOW $25.92 |
TARGET | |||||
|
|||||
Franking for last dividend paid out: 0% |
OTHER COMPANIES IN THE SAME SECTOR | |||
4DX . AT1 . BRN . CAT . CBL . CGS . CMP . COH . CSX . CU6 . CYC . EBR . EMV . EYE . IDX . IME . IMR . IPD . LDX . MX1 . NAN . ONE . PCK . PEB . PGC . PME . RMD . SOM . TRJ . UBI . VHT . VTI . |
FNARENA'S MARKET CONSENSUS FORECASTS
Title | FY24 Forecast |
FY25 Forecast |
---|---|---|
EPS (cps) | 40.5 | xxx |
DPS (cps) | 37.7 | xxx |
EPS Growth | N/A | xxx |
DPS Growth | N/A | xxx |
PE Ratio | 65.8 | xxx |
Dividend Yield | 1.4% | xxx |
Div Pay Ratio(%) | 93.1% | xxx |
All estimates have been converted into AUD by FNArena at present FX values.
Last ex-div: 05/12 - ex-div 16.59c (franking 0%)
HISTORICAL DATA ARE ALL IN AUD
Copyright © 2024 FactSet UK Limited. All rights reserved
Title | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
---|---|---|---|---|---|---|
EPS Basic | xxx | xxx | xxx | xxx | xxx | 39.5 |
DPS All | xxx | xxx | xxx | xxx | xxx | 43.4 |
Sales/Revenue | xxx | xxx | xxx | xxx | xxx | 1,447.4 M |
Book Value Per Share | xxx | xxx | xxx | xxx | xxx | 282.8 |
Net Operating Cash Flow | xxx | xxx | xxx | xxx | xxx | 217.0 M |
Net Profit Margin | xxx | xxx | xxx | xxx | xxx | 15.76 % |
EPS Basic
DPS All
Sales/Revenue
Book Value Per Share
Net Operating Cash Flow
Net Profit Margin
Title | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
---|---|---|---|---|---|---|
Return on Capital Employed | xxx | xxx | xxx | xxx | xxx | 14.28 % |
Return on Invested Capital | xxx | xxx | xxx | xxx | xxx | 13.45 % |
Return on Assets | xxx | xxx | xxx | xxx | xxx | 11.37 % |
Return on Equity | xxx | xxx | xxx | xxx | xxx | 14.28 % |
Return on Total Capital | xxx | xxx | xxx | xxx | xxx | 18.07 % |
Free Cash Flow ex dividends | xxx | xxx | xxx | xxx | xxx | -132.4 M |
Return on Capital Employed
Return on Invested Capital
Return on Assets
Return on Equity
Return on Total Capital
Free Cash Flow ex dividends
Title | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
---|---|---|---|---|---|---|
Short-Term Debt | xxx | xxx | xxx | xxx | xxx | 20 M |
Long Term Debt | xxx | xxx | xxx | xxx | xxx | 116 M |
Total Debt | xxx | xxx | xxx | xxx | xxx | 136 M |
Goodwill - Gross | xxx | xxx | xxx | xxx | xxx | - |
Cash & Equivalents - Generic | xxx | xxx | xxx | xxx | xxx | 113 M |
Price To Book Value | xxx | xxx | xxx | xxx | xxx | 8.80 |
Short-Term Debt
Long Term Debt
Total Debt
Goodwill - Gross
Cash & Equivalents - Generic
Price To Book Value
Title | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
---|---|---|---|---|---|---|
Capex | xxx | xxx | xxx | xxx | xxx | 192.5 M |
Capex % of Sales | xxx | xxx | xxx | xxx | xxx | 13.30 % |
Cost of Goods Sold | xxx | xxx | xxx | xxx | xxx | 586 M |
Selling, General & Admin. Exp & Other | xxx | xxx | xxx | xxx | xxx | 552 M |
Research & Development | xxx | xxx | xxx | xxx | xxx | 159 M |
Investments - Total | xxx | xxx | xxx | xxx | xxx | 65 M |
Capex
Capex % of Sales
Cost of Goods Sold
Selling, General & Admin. Exp & Other
Research & Development
Investments - Total
EXPERT VIEWS
Display All Commentary
Sentiment Indicator
No. Of Recommendations
FPH STOCK CHART
FNArena News on FPH
1 |
Rudi’s View: Quality Reigns, And How To Identify ItMay 01 2024 - Rudi's View |
2 |
Australian Broker Call *Extra* Edition – Mar 28, 2024Mar 28 2024 - Daily Market Reports |
3 |
Rudi’s View: Healthcare Under The ScannerMar 13 2024 - Rudi's View |
4 |
Rudi’s View: Healthcare, REITs, Uranium & BanksJan 24 2024 - Rudi's View |
5 |
Treasure Chest: AnsellJan 18 2024 - Treasure Chest |
Latest Medical Equipment & Devices News
1 |
ResMed Silences The DoubtersApr 29 2024 - Australia |
2 |
Dr Boreham’s Crucible: 4D MedicalApr 23 2024 - Small Caps |
3 |
Uptrend Resumed For ResMedMar 19 2024 - Technicals |
4 |
Dr Boreham’s Crucible: CochlearFeb 28 2024 - Australia |
5 |
Rudi Interviewed: Ongoing Potential In Technology & GrowthFeb 19 2024 - Rudi's View |
6 |
Dr Boreham’s Crucible: ArtryaFeb 15 2024 - Small Caps |
7 |
ResMed Recovery Turns Into Hollywood ScriptJan 31 2024 - Australia |
8 |
ResMed Makes A ComebackJan 29 2024 - Australia |
9 |
ResMed: The Recovery Has BegunJan 23 2024 - Technicals |
10 |
Dr Boreham’s Crucible: Pro MedicusOct 23 2023 - Australia |